XSHE300595
Market cap2.04bUSD
Jan 16, Last price
16.65CNY
1D
-0.30%
1Q
-13.42%
IPO
43.04%
Name
Autek China Inc
Chart & Performance
Profile
Autek China Inc. engages in the research, development, production, and sale of eye vision and related supporting products. It offers optometry medical devices, such as orthokeratology lenses for vision correction and myopia control. The company was founded in 2001 and is based in Hefei, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 1,737,168 13.89% | 1,525,319 17.78% | |||||||
Cost of revenue | 886,211 | 726,346 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 850,958 | 798,973 | |||||||
NOPBT Margin | 48.99% | 52.38% | |||||||
Operating Taxes | 118,126 | 98,783 | |||||||
Tax Rate | 13.88% | 12.36% | |||||||
NOPAT | 732,832 | 700,190 | |||||||
Net income | 666,600 6.85% | 623,848 12.46% | |||||||
Dividends | (125,233) | (124,377) | |||||||
Dividend yield | 0.62% | 0.40% | |||||||
Proceeds from repurchase of equity | (9,074) | (1) | |||||||
BB yield | 0.04% | 0.00% | |||||||
Debt | |||||||||
Debt current | 16,891 | 74,358 | |||||||
Long-term debt | 343,515 | 301,976 | |||||||
Deferred revenue | 44,093 | 22,267 | |||||||
Other long-term liabilities | 1 | 122 | |||||||
Net debt | (3,318,392) | (1,916,077) | |||||||
Cash flow | |||||||||
Cash from operating activities | 723,384 | 651,717 | |||||||
CAPEX | (197,933) | ||||||||
Cash from investing activities | (602,660) | ||||||||
Cash from financing activities | (618,434) | 1,300,483 | |||||||
FCF | 1,774,172 | (306,786) | |||||||
Balance | |||||||||
Cash | 3,173,960 | 2,292,411 | |||||||
Long term investments | 504,839 | ||||||||
Excess cash | 3,591,940 | 2,216,145 | |||||||
Stockholders' equity | 3,338,263 | 3,070,582 | |||||||
Invested Capital | 1,605,539 | 2,581,903 | |||||||
ROIC | 35.00% | 35.41% | |||||||
ROCE | 17.19% | 16.64% | |||||||
EV | |||||||||
Common stock shares outstanding | 893,326 | 870,931 | |||||||
Price | 22.58 -36.75% | 35.70 -37.77% | |||||||
Market cap | 20,171,300 -35.12% | 31,092,247 -36.17% | |||||||
EV | 17,212,571 | 29,541,452 | |||||||
EBITDA | 959,465 | 898,497 | |||||||
EV/EBITDA | 17.94 | 32.88 | |||||||
Interest | 10,125 | 468 | |||||||
Interest/NOPBT | 1.19% | 0.06% |